Strand Therapeutics

@Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

Strand CEO and co-founder @DrSynbio spoke about why quality beats speed in the China biotech debate and the importance of building fundamentally revolutionary medicines that are genuinely hard to replicate. Read his take in In Vivo, a @Citeline publication, as senior reporter @davidwild77 looks at how Western biotechs are defining their strategy against China's biotech surge: insights.citeline.com/in-vivo/busine…

@DrSynbio @EY_US Read more: ey.com/en_us/newsroom…

Congratulations to our co-founder and CEO, @DrSynbio, on being named an @EY_US Entrepreneur Of The Year® 2026 New England Award winner! This recognition reflects a mission that every person at Strand shows up for every day: programming mRNA to sense, decide, and act inside the body, so that therapies reach more patients, treat more diseases, and do so more scalably than ever before. That mission is what keeps us moving forward.

Strand was founded at MIT, so welcoming students from MIT's BioCEL and Ron Weiss's lab this past May felt a little like a homecoming. The group toured our facility, connected with the team, and got a firsthand look at programmable mRNA medicine in action. The next wave of scientists in this space is a promising one.

Building a great place to work is a team effort. We're honored to have been named the #12 best medium-sized company to work for by the @BosBizJournal, and grateful to the people behind the science and the culture. #BBJBPTW

For Cancer Immunotherapy Awareness Month, Strands participated in today's #WearWhite campaign honoring the dedication of patients, caregivers, and researchers working to improve cancer treatment

This is the standard our co-founder and CEO, @DrSynbio, holds Strand to – and it’s the lens through which our team thinks about everything from how we design drugs to how we push for the regulatory reform that gets treatments to patients faster. Jake joined @tferriss to talk through the science, the clinical results, and what it will actually take to make that goal a reality. Listen here: tim.blog/2026/06/02/jak…

What if off-target effects weren’t a delivery problem but a programming problem? Our programmable mRNA platform uses molecular sensors to make sure only tumor cells can “read” the message and produce the protein that triggers their destruction. Healthy cells ignore the mRNA altogether. @GENbio featured our approach in their recent piece on next-gen therapeutic modalities: genengnews.com/topics/drug-di…

"We are standing right now on the precipice of a revolution in genetic medicine." Strand CEO @DrSynbio on @tferriss' podcast. Full episode: podcasts.apple.com/us/podcast/868…

@Nasdaq Read more: businesswire.com/news/home/2026…

Hard to miss Kunal Bhatia on the @Nasdaq tower in Times Square, featuring his appointment as Chief Financial Officer. In Kunal’s words, “I joined Strand because I believe we are one of the most innovative biotech companies today; importantly, we are prosecuting a big vision with rigor and intense focus.” Glad to have him helping lead this next chapter

What if a medicine could decide when and where to activate inside your body? Strand co-founder and CEO @DrSynbio joined the @ProgressPotent1 podcast with @irat1onal to discuss programmable mRNA therapeutics, Strand’s origins at MIT, and what early clinical results mean for the future of genetic medicine. Listen here: podcasts.apple.com/us/podcast/pro…

Thursday morning, our Chief Medical Officer @jasonlukemd joins leaders from @IN8bio, @MedicalCollege, and @advarra for a @FiercePharma webinar on translating cutting-edge oncology science into operationally executable trials. The conversation will cover adaptive trial design, patient access, and what it actually takes to run next-generation oncology studies at scale. 🔬Don't miss it! Register at the link below. fiercepharma.com/premium/webina…

mRNA therapeutics are a powerful modality. It's also one where you can’t take shortcuts if you want to succeed, and circular RNA (circRNA) is no different. In a new interview with @PharmaScrip’s @awmcconaghie, our co-founder, President, and Head of R&D @tasuku_kitada breaks down what it takes to build an in vivo CAR-T platform that can deliver in the clinic: optimized circRNA architecture, targeted lipid nanoparticle (LNP) delivery, and programmable safety controls built directly into the construct. With major pharma bets pouring into the space, Tasuku makes the case that the companies that win will be the ones that did the engineering work before rushing to the clinic. Read more: insights.citeline.com/scrip/advanced…

Circular RNA is emerging as one of the most exciting frontiers in gene and cell therapy. At Strand, we've been building on it for years. BioWorld's @MarJungle covered the latest advances at #ASGCT2026, including a conversation with our co-founder, President, and Head of R&D @tasuku_kitada. They discuss how Strand is using circRNA to power STX-005, our in vivo CAR-T program designed to be a redosable, off-the-shelf approach to cell therapy. Read more: bioworld.com/articles/73126…

Strand stays committed to fostering the next generation of scientists. Shoutout to Strands Eloise, Gautam and Daniel for participating as judges for the MSEF Middle School Science Fair this past weekend!

Programmable RNA is coming for in vivo CAR-T. Tomorrow at #ASGCT2026, our Principal Scientist Ashlesha Odak, Ph.D. is presenting preclinical NHP data showing how programmable circRNA, combined with a targeted LNP approach, can generate functional CAR-T cells in vivo with integrated safety controls. No cell extraction, no manufacturing facility. This is pioneering what's possible in programmable genetic medicine. Watch the presentation to find out for yourself: 📢 LNPs for in vivo CAR-T applications 📅 Tuesday, May 12, at 9:00-9:15 am ET 📍 MCEC Room 210 ABC (Level 2) Presentation abstract can be found here: annualmeeting.asgct.org/abstract

Our CEO @DrSynbio sat down with @FierceBiotech’s @Angus_Fierce to talk about the regulatory and manufacturing barriers slowing first-in-human clinical trials in the U.S., and what a more efficient pathway to first-in-human trials could mean for American patients. Read the conversation here: fiercebiotech.com/biotech/concer…

You can find the full agenda here: syntheticbiologysummit.com/2026/sessions

How are advances in sequence design, delivery, and manufacturing closing the gap between computational insight and real-world medicines? Join @tasuku_kitada, co-founder, President, and Head of R&D at Strand Therapeutics, at @SynBioBeta on Wednesday, May 6, for a panel on one of the most important questions in programmable medicine. We hope to see you there!